Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II anastrozole study in hormone receptor-positive recurrent/metastatic gynecological cancers
2011-003192-11Phase 2Completed
- Sponsor
- University of Sydney
- Start
- Jul 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anastrozole in gynecological cancer, ovarian cancer, endometrial cancer (EC) and 3 more, sponsored by University of Sydney. Primary endpoints: Clinical benefit, Overall response rate and 2 more. Started Jul 2012; status: completed.
02
Drugs
anastrozole
03
Conditions
gynecological cancerovarian cancerendometrial cancer (EC)Bone and soft tissue sarcomaOvarian sex-cord stromal tumor (SCST)
Beyond the preview
Go deeper on 2011-003192-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003192-11.